CCR5 Antagonist Has Potential for Multiple Therapeutic Indications
Washington-based CytoDyn Inc. today announced that the journal Frontiers in Immunology published an Original Research paper that found 'Leronlimab stabilized cell surface CCR5, leading to an increase in the levels of circulating and tissue-resident CCR5+CD4+ T cells in vivo in Leronlimab-treated macaques.'
Notably, the results of the study outlined in the research paper published on November 19, 2021, are as follows:
- Establish two CCR5 receptor occupancy calculation methods for longitudinal monitoring of anti-CCR5 therapeutic antibody blockade efficacy in both macaques and humans;
- Demonstrate that CCR5+CD4+ T cell levels temporarily increase with leronlimab treatment; and
- Facilitate future detailed investigations into the immunological impacts of CCR5 inhibition in multiple pathophysiological processes.
CytoDyn's Chief Medical Officer, Scott A. Kelly M.D., commented in a press release, "We will relentlessly pursue the various indications for leronlimab to realize its full therapeutic potential."
"Our continued work on the mechanism of action of leronlimab continues to lay the foundation for more exciting opportunities of leronlimab for patients and our shareholders."
CCR5 plays a critical role in the ability of HIV to enter and infect healthy T-cells.
In addition, it appears to be implicated in tumor metastasis and immune-mediated illnesses, such as NASH.
For example, the U.S. FDA designated Leronlimab for Fast Track Approval to treat HIV and metastatic cancer in February 2021.
CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications using leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.